Luha Private Equity

Overview

Luha Private Equity is a Seoul-based private equity firm specializing in early-stage investments across South Korea and the United States. The firm focuses on sectors such as biotechnology, healthcare, diagnostics, and digital healthcare, aiming to support companies with high growth potential. Luha Private Equity employs a comprehensive investment strategy that includes M&A, buyouts, growth capital, mezzanine financing, and event-driven investments. The firm seeks to maximize returns by acquiring companies with strong growth prospects and implementing operational improvements. Additionally, Luha Private Equity invests in leading private companies from growth sectors, providing extensive support from Series A to IPO by offering investor relations support and helping explore new markets through global relationships. The firm also seeks downside protection while sharing any equity upside by investing in convertible bonds, bonds with warrants, redeemable convertible preferred shares, and implements safeguard measures such as appointing a member into the board of directors, adding prefixing clauses, and rights to request sufficient financial/operational data. Luha Private Equity's investment philosophy centers on rigorous fundamental analysis coupled with close working relationships with businesses, pursuing mutually beneficial partnerships for all involved parties. The firm aims to generate attractive investment returns both in and outside of Korea by hiring professionals with the highest standards of excellence. Luha Private Equity's members hold the conviction that being different will lead to investment success beyond comparison, employing various investment strategies across multiple asset classes to build one of the strongest and distinguished investment platforms in Korea. The firm has a track record of significant investments, including the acquisition of a 26% stake in LabGenomics, a molecular diagnostics specialist company, in January 2023. This strategic move was aimed at entering the U.S. market and expanding into the digital healthcare sector based on diagnostic data. The acquisition was completed through a management rights transfer contract worth 122.6 billion KRW, securing approximately 30% control and enabling stable management rights. Luha Private Equity's investment in LabGenomics aligns with its strategy to enter the U.S. market, bringing in experts specialized in enhancing corporate value, and is expected to improve corporate value going forward. The firm continues to focus on investments that offer high growth potential and align with its strategic objectives in the biotechnology and healthcare sectors.